Acta Dermatovenerol APA

Acta Dermatovenerologica
Alpina, Pannonica et Adriatica

2025;34:79-82
doi: 10.15570/actaapa.2024.29

# Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder: a case report and literature review

Katarina Trčko[1]✉, Nuša Lukinovič[1], Daja Šekoranja[2]

[1]*Department of Dermatology, Maribor University Medical Center, Maribor, Slovenia.* [2]*Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.*

**Abstract**

Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder (PCSM-LPD) is characterized by a slow-growing and asymptomatic solitary plaque or tumor, usually involving the head, neck, or upper extremities. The diagnosis is established based on clinical presentation, histopathological features including pleomorphic morphology and CD4-positive immunophenotype of neoplastic T lymphocytes, and molecular analysis showing clonally rearranged T-cell receptor (TCR) genes. Plaques typical of mycosis fungoides are essentially absent. Treatment options include surgical excision, radiotherapy, and topical or intralesional steroids. Because the disease is indolent, aggressive diagnostic tests and systemic treatments are not recommended. We present a case of PCSM-LPD in a previously healthy young man that spontaneously regressed after a biopsy.

**Keywords:** primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder, primary cutaneous lymphoma, T-cell lymphoma, lymphoproliferative disorder, spontaneous regression

**Received:** 16 September 2024 | **Returned for modification:** 7 October 2024 | **Accepted:** 11 October 2024

## Introduction

Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder (PCSM-LPD) is a fairly recently recognized but nonetheless quite frequent entity (second only to mycosis fungoides among T-cell proliferative disorders in the skin) (1). It usually occurs in adults as a solitary nodule or plaque, most commonly in the head and neck region, but it may also appear on the trunk or extremities (1). Histologically, it is defined by the predominance of small to medium-sized CD4-positive pleomorphic T cells without prior or concurrent patches and plaques typical of mycosis fungoides (1). In the 2005 World Health Organization–European Organization for Research and Treatment of Cancer (WHO-EORTC) classification, it was classified as primary cutaneous CD4-positive small/medium pleomorphic T-cell lymphoma. It was considered a rare, poorly defined disease with uncertain malignant potential (2). In the revised WHO-EORTC classification of 2018, the term "lymphoma" was changed to "lymphoproliferative disorder" due to its benign course (3). PCSM-LPD is now considered a relatively common cutaneous T-cell lymphoma (CTCL) with a favorable prognosis and no reported risk of secondary lymphomas (4). Here, we present a case of spontaneous regression of PCSM-LPD after a biopsy in a young man.

## Case report

A 22-year-old man presented with a solitary skin lesion on the right upper arm that had been present for 2 months. The family history of skin disease was negative. Physical examination revealed a well-demarcated erythematous plaque with a diameter of 23 mm on the proximal third of the lateral aspect of the right upper arm (Fig. 1a). The patient had no other skin lesions or systemic symptoms.

The biopsy revealed an unremarkable epidermis and a dense, diffuse, mixed-cell inflammatory infiltrate within the entire thickness of the dermis. The infiltrate was composed predominantly of small to medium-sized CD3+ T lymphocytes, exhibiting somewhat pleomorphic cell morphology (Figs. 2a, b). In the background were less numerous CD20+ B lymphocytes, histiocytes, and eosinophilic granulocytes.

The pleomorphic T lymphocytes showed CD3+ (Fig. 2c), CD4+ (Fig. 2d), CD8–, and CD30– immunophenotypes and were predominantly positive for CD2, CD5, and CD7, indicating only a slight down-regulation of CD2 and CD7 expression. Programmed cell death protein 1 (PD1) was expressed by a subset of cells (Fig. 2e), focally arranged in small clusters. The Ki-67 proliferation index was low (approximately 5%). Molecular genetic analysis revealed monoclonal rearrangement in the *TcR-gamma* gene. B-lymphocytes were polyclonal.

Laboratory tests, including a complete blood cell count with the differential, liver function tests, lactate dehydrogenase level, and serum protein electrophoresis, were all within the normal limits. Additional immunophenotyping of a peripheral blood sample was performed and showed no abnormalities. Computed tomography (CT) of the thorax and abdomen ruled out the involvement of other organs. Based on the clinical presentation, histomorphological features, and the immunophenotype of the lymphocytic infiltrate as well as monoclonality of T lymphocytes, a diagnosis of PCSM-LPD was made.

About 1 month after the biopsy, partial regression of the lesion was observed (Fig. 1b). After 3 months it had completely disappeared (Fig. 1c). At the time of writing this manuscript, the patient is being monitored every three months and remains in clinical remission.

## Discussion

PCSM-LPD is the second most common CTCL with indolent behavior. It accounts for approximately 6% of all CTCLs, although the incidence of the disease is probably underestimated (3, 5). PCSM-LPD shows no sex predilection (6). The disease usually begins later in life, with a median age of 59 years, but there are also cases

✉ Corresponding author: katarina.trcko@gmail.com

reported in children and even infants (4, 7).

The etiopathogenesis of PCSM-LPD is unclear. There are reports of PCSM-LPD occurring at the site of a melanoma excision scar (8) and of PCSM-LPD coexisting with myelodysplastic syndrome and transforming into chronic myelomonocytic leukemia (9). It can also be drug-induced by methotrexate-etanercept combination (10), vemurafenib (11), interleukin-2 therapy for metastatic melanoma (12), and immunosuppressive therapy (cyclosporine, prednisolone, and azathioprine) after heart transplantation (13). In our case, the patient was previously a healthy young man and was not taking any medication.

Clinically, PCSM-LPD can present with a wide variety of symptoms and signs. Most commonly, it presents as a slow-growing erythematous or violaceous papule, plaque, nodule, or tumor affecting the head, neck, upper extremities, or upper trunk (14). Most lesions are asymptomatic and are rarely associated with pain, pruritus, or ulceration (6). Approximately 7% of patients have multifocal lesions (4).

The diagnosis of PCSM-LPD is based on clinical presentation and histomorphological and immunohistochemical features. Histology usually reveals a dense nodular or diffuse infiltrate of small or medium-sized pleomorphic T lymphocytes with mild to moderate atypia and a low proliferation rate (Ki-67 index < 20%) (3). In addition to T lymphocytes, B lymphocytes, plasma cells, histiocytes, and eosinophils may also be present. Large pleomorphic cells may be present but account for less than 30% of the infiltrate. The infiltrate involves the entire dermis and can extend to the subcutis (3). In most cases, epidermotropism is not present but may occur focally, as was the case in our patient (15). T lymphocytes have a CD3+, CD4+, CD8–, and CD30– immunophenotype. Partial or complete loss of CD7 and rarely CD5 is possible (16). The T lymphocytes express follicular helper T-cell markers, including PD-1




Figure 1 | Figure 1. (A) Well-defined erythematous plaque on the upper extremity, (B) partial regression of the lesion, (C) complete regression of the lesion, with two pink scars corresponding to the site of biopsy.




Figure 2 | (A) Scanning magnification of a dense intradermal infiltrate (hematoxylin and eosin, 2.5×), which is composed predominantly of (B) small to medium-sized pleomorphic T cells with a mixed cellular background (hematoxylin and eosin, 40×); neoplastic T cells express (C) CD3 (20×), (D) CD4 (20×), and (E) programmed cell death protein 1 (PD1) (20×).

(CD279), B-cell lymphoma 6 (BCL6), and chemokine (C-X-C motif) ligand 13 (CXCL13) (17), but they lack the expression of chemokine receptor CXCR5 (18). In addition, positive nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) nuclear staining and clonal rearrangement of T-cell receptor genes are highly characteristic of PCSM-LPD (19, 20).

Basic blood tests should be performed in all patients. In some patients, additional staging with CT scans or positron emission tomography scans, bone marrow biopsy, and immunophenotyping of a peripheral blood sample is performed. However, this is not necessary in all patients, and the extent of staging investigations should be individualized based on the patient's blood test and physical examination (16, 19). The patient presented had normal laboratory results, normal results of immunophenotyping of the peripheral blood sample, and no abnormalities on the CT scans.

Basal cell carcinoma, adnexal tumors and cysts, and Jessner lymphocytic infiltration may clinically resemble PCSM-LPD (4). Pseudolymphoma, primary cutaneous acral CD8+ T-cell lymphoma, peripheral T-cell lymphoma not otherwise specified (PTCL, NOS), angioimmunoblastic T-cell lymphoma, primary cutaneous follicle center lymphoma, primary cutaneous marginal zone lymphoma, and tumoral stage of mycosis fungoides should also be considered in the differential diagnosis (18, 20-23).

There is no consensus on the optimal treatment for PCSM-LPD. The most commonly used treatment options are surgical excision, radiotherapy, and topical or intralesional steroids. For multiple or recurrent lesions, phototherapy and topical steroids are recommended (15). Oral treatment with doxycycline is also reported to be a safe and effective treatment option (24–26). In the past, aggressive systemic treatments such as chemotherapy were also used. Nowadays, such aggressive systemic treatments are no longer recommended because their risk outweighs the potential benefits (4, 27). In our case, the skin lesion regressed spontaneously after biopsy and the patient required no further treatment. Beltzung et al. reported that complete regression after biopsy occurred in 16.7% of patients and partial regression in 8.3% (28). The exact mechanism of the spontaneous regression is not known. The activation and enhancement of the host immune response, especially the T cell-mediated response, is thought to be involved (29).

A recent systematic review reported that 95.5% of patients recovered completely without relapse, whereas the remaining 4.5% of patients showed partial improvement after treatment. In addition, a 5-year survival rate of 100% was reported without systemic involvement (4). In the case of generalized disease, rapid progression, or resistance to treatment, an alternative diagnosis of peripheral T-cell lymphoma, unspecified, should be considered (3, 6). Histopathology findings associated with unfavorable prognosis are high proliferative index, low CD40 expression, and infiltrates lacking B-cells and CD8-positive T cells (6). There is no consensus on the duration of follow-up for patients with PCSM-LPD. Because the prognosis is excellent and relapses are rare, a follow-up of 2 years is recommended (30, 31).

## Conclusions

Currently, PCSM-LPD remains a poorly understood disease with no clear diagnostic or treatment guidelines. In the future, accurate diagnostic criteria and optimal management should be defined to avoid misdiagnosis, potentially unnecessary staging, and unnecessary aggressive treatment. Our case report emphasizes that clinical observation after biopsy could be an initial treatment strategy for PCSM-LPD because spontaneous regression after biopsy is possible.

## References


1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms. Leukemia. 2022;36:1720–48.
2. Willemze R. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105:3768–85.
3. Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–14.
4. Surmanowicz P, Doherty S, Sivanand A, Parvinnejad N, Deschenes J, Schneider M, et al. The clinical spectrum of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder: an updated systematic literature review and case series. Dermatology. 2021;237:618–28.
5. Williams VL, Torres-Cabala CA, Duvic M. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol. 2011; 12:389–401.
6. Salah E. Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder: where do we stand? A systematic review. JDDG J Dtsch Dermatol Ges. 2019;17:123–36.
7. Li D, Guo B, Li D, Chang C, Lu Q. Primary cutaneous CD4+ small-to-medium-sized pleomorphic T-cell lymphoma: a rare case report of infant. J Clin Pathol. 2015; 68:855–8.
8. Aria AB, Wilmas K, Kim EJ, Aung PP, Duvic M. The development of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder at the site of a melanoma excision scar. Dermatol Online J. 2018;24:13030/qt6mfod1mb.
9. Wawrzycki B, Chodorowska GY, Pietrzak A, Jazienicka I, Skomra D, Kowal M, et al. Therapeutic hotline: primary cutaneous CD4+ small/medium-sized pleomorphic T cell lymphoma coexisting with myelodysplastic syndrome transforming into chronic myelomonocytic leukemia successfully treated with cyclophosphamide: cutaneous CD4 pleomorphic T cell lymphoma. Dermatol Ther. 2010;23: 676–81.
10. Ma H, Qiu S, Lu R, Feng P, Lu C. Methotrexate and etanercept-induced primary cutaneous CD4 positive small/medium-sized pleomorphic T-cell lymphoma. An Bras Dermatol. 2016;91:368–71.
11. Garrido MC, Riveiro-Falkenbach E, Ruano Y, Ortiz P, Rodriguez-Peralto JL. Primary cutaneous small/medium CD4+ T-cell lymphoma occurring during treatment with vemurafenib for advanced melanoma. Am J Dermatopathol. 2015;37:440–3.
12. Davick JJ, Gaughan E, Barry M, Gru AA. Primary cutaneous small/medium CD4+ T-cell lymphoproliferative disorder occurring in a patient with metastatic melanoma. Am J Dermatopathol. 2018;40:60–3.
13. Shakerian B, Razavi N, Mandegar MH. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma following heart transplantation. 2017;8:168–9.
14. Gru AA, Wick MR, Eid M. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder—clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37:39–48.
15. Alberti-Violetti S, Torres-Cabala CA, Talpur R, Corti L, Fanoni D, Venegoni L, et al. Clinicopathological and molecular study of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. J Cutan Pathol. 2016;43:1121–30.
16. Geller S, Myskowski PL, Pulitzer M, Horwitz SM, Moskowitz AJ. Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chin Clin Oncol. 2019;8:5.
17. Rodríguez Pinilla SM, Roncador G, Rodríguez-Peralto JL, Mollejo M, García JF, Montes-Moreno S, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33:81–90.
18. Krenács D, Bakos A, Török L, Kocsis L, Bagdi E, Krenács L. Neoplastic cells of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma lack expression of follicular T-helper cell defining chemokine receptor CXCR5. Acta Derm Venereol. 2014;96:850–2.

19. Magro CM, Momtahen S. Differential NFATc1 expression in primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma and other forms of cutaneous T-cell lymphoma and pseudolymphoma. Am J Dermatopathol. 2017; 39:95–103.
20. Shi H, Zhang J, Xiong J, Gan L, Jiang Y, Xu X, et al. Clinicopathological analysis of primary cutaneous CD4-positive small/medium pleomorphic T-cell lymphoproliferative disorder: a retrospective study of 22 patients. Int J Dermatol. 2021;60: 497–502.
21. Besch-Stokes JG, Costello CM, Severson KJ, Bhullar P, Montoya J, Butterfield RJ, et al. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: diagnosis and management. J Am Acad Dermatol. 2022;86:1167–9.
22. Kim HJ, Han JH, Min SK. Differential diagnosis of primary cutaneous CD4+ small/medium T-cell lymphoproliferative lesions: a report of three cases. Blood Res. 2017;52:326.
23. Lan TTH, Brown NA, Hristov AC. Controversies and considerations in the diagnosis of primary cutaneous CD4+ small/medium T-cell lymphoma. Arch Pathol Lab Med. 2014;138:1307–18.
24. Toberer F, Hartschuh W, Hadaschik E. Primary cutaneous CD4+ small- to medium-sized pleomorphic T-cell lymphoma: temporary remission by oral doxycycline. JAMA Dermatol. 2013;149:956.
25. Escanilla C, Guavita Falla PM, Cevallos C, Ávalos Jobet N, Bobadilla Bruneau F. Primary cutaneous CD4-positive small/medium T-cell lymphoproliferative disorder: the first-reported Latin-American case with response to doxycycline. Clin Case Rep. 2019;7:2405–9.
26. Sarac E, Demirkesen C. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a case with multiple tumors. An Bras Dermatol. 2023; 98:720–2.
27. Virmani P, Jawed S, Myskowski PL, Horwitz S, Skripnik Lucas A, Moskowitz A, et al. Long-term follow-up and management of small and medium-sized CD 4+ T cell lymphoma and CD 8+ lymphoid proliferations of acral sites: a multicenter experience. Int J Dermatol. 2016;55:1248–54.
28. Beltzung F, Ortonne N, Pelletier L, Beylot-Barry M, Ingen-Housz-Oro S, Franck F, et al. Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorders: a clinical, pathologic, and molecular study of 60 cases presenting with a single lesion: a multicenter study of the French Cutaneous Lymphoma Study Group. Am J Surg Pathol. 2020;44:862–72.
29. Ricci SB, Crichiari U. Spontaneous regression of malignant tumors: importance of the immune system and other factors (review). Oncol Lett. 2010;1:941–5.
30. Çetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol. 2012;36:109–16.
31. Kim J, Jeong M, Jun D, Lee M, Shin D, Kim W, et al. Primary cutaneous CD4+ small/medium T-cell lymphoma: a case report. Arch Craniofacial Surg. 2021;22:199–203.